Biodesix, Inc. (NASDAQ:BDSX) Shares Acquired by AIGH Capital Management LLC

AIGH Capital Management LLC increased its holdings in shares of Biodesix, Inc. (NASDAQ:BDSX) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,179,812 shares of the company’s stock after buying an additional 500,000 shares during the period. Biodesix comprises 3.0% of AIGH Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. AIGH Capital Management LLC owned approximately 4.25% of Biodesix worth $9,455,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in BDSX. Wilmington Savings Fund Society FSB acquired a new stake in shares of Biodesix in the third quarter valued at $10,849,000. Perkins Capital Management Inc. increased its holdings in Biodesix by 46.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock worth $1,622,000 after purchasing an additional 335,429 shares during the period. Geode Capital Management LLC raised its position in Biodesix by 50.7% in the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after purchasing an additional 270,724 shares in the last quarter. Stephens Inc. AR purchased a new position in shares of Biodesix in the 4th quarter valued at about $303,000. Finally, HighTower Advisors LLC grew its position in shares of Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after buying an additional 22,500 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 128,702 shares of company stock valued at $118,406. Insiders own 69.20% of the company’s stock.

Biodesix Price Performance

Shares of NASDAQ:BDSX opened at $0.67 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. Biodesix, Inc. has a 12 month low of $0.64 and a 12 month high of $2.04. The firm has a market capitalization of $97.81 million, a P/E ratio of -1.72 and a beta of 1.10. The company’s fifty day moving average price is $0.89 and its 200 day moving average price is $1.28.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The firm had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. As a group, sell-side analysts predict that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Biodesix in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Biodesix presently has an average rating of “Buy” and an average price target of $2.95.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.